Abstracts tagged "B-Lymphocyte"

Abstract Number: 0291 • ACR Convergence 2020
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
Morgane Humbel¹, Florence Bellanger², Craig Fenwick², Alice Horisberger², Camillo Ribi² and Denis Comte², ¹CHUV, Lausanne, Vaud, Switzerland, ²CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies. For this reason, anti-B cell therapy seems to be…
Abstract Number: 0999 • ACR Convergence 2020
CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells
Claire Rempenault¹, Julie Mielle², Kristina Schreiber¹, Pierre Corbeau³, Jacques Morel⁴, Claire Daien⁴ and Rachel Audo², ¹Rheumatology, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³immunology, Nimes, France, ⁴Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: Human regulatory B cells still need to be characterized. Given the absence of phenotypical definition, a functional definition based on their ability to secrete…
Abstract Number: 0292 • ACR Convergence 2020
Exhausted pSTAT5-IFNα Signaling Pathways in SLE Patients Are Correlated with Age-associated B Cells and Disease Activity
Samantha Slight-Webb¹, Miles Smith², Kevin Thomas¹, Susan Macwana¹, Holden Maecker³, Paul Utz⁴, Judith James⁵ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by periods of elevated and suppressed clinical symptoms. Specific cell subsets, such as CD11c+ age-associated…
Abstract Number: 1060 • ACR Convergence 2020
B-cell-rich Inflammatory Myopathies in Adults: Striking Association with Connective Tissue Diseases
Pat Korathanakhun¹, Océane Landon-Cardinal², Valérie Leclair³, Benjamin Ellezam⁴, Alain Meyer⁵, Josiane Bourré-Tessier², Anne-Marie Mansour⁶, Sandrine Larue⁷, François Grand'Maison⁷, Rami Massie⁸, Matthieu Le Page⁹, Catherine Isabelle⁷, Nathalie Routhier⁶, Flavie Roy¹⁰, Minoru Satoh¹¹, Marvin Fritzler¹², Jean-Luc Senécal², Yves Troyanov¹³, Marie Hudson³, Jason Karamchandani¹⁴ and Erin O'Ferrall⁸, ¹Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ⁴Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, ⁵Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ⁶Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada, ⁷Hôpital Charles-Lemoyne, Longueuil, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Centre hospitalier de Lanaudière, Saint-Charles-Borromée, QC, Canada, ¹⁰Uiversité de Montréal, Montreal, QC, Canada, ¹¹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ¹⁴Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada
Background/Purpose: Myositis with significant B-cell infiltrates on muscle biopsy has scarcely been described in adults. Radke (2018) found B cells in adult dermatomyositis (DM) and…
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 1227 • ACR Convergence 2020
Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors
Borja Hernandez-Breijo¹, Chamaida Plasencia², Victoria Navarro-Compán³, Israel Nieto-Gañán⁴, Cristina Sobrino⁵, Ana Martínez-Feito⁶, Carlota García-Hoz⁴, Paloma Lapuente-Suanzes⁴, Javier Bachiller-Corral⁷, Gema Bonilla², Cristina Pijoán-Moratalla⁷, Garbiñe Roy⁴, Mónica Vázquez⁷, Alejandro Balsa², Luisa M Villar⁴, Dora Pascual-Salcedo⁸ and Eulalia Rodríguez-Martín⁴, ¹Immuno-rheumatology Research group. IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ³Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁴Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ⁵Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁶Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: Biological therapies, as TNF inhibitors (TNFi) are increasing remission rates in rheumatoid arthritis (RA) patients although these are still limited. This study aims to…
Abstract Number: 0460 • ACR Convergence 2020
Lymphocyte Clonal Expansion Distinguishes Different Forms of Uveitis
Michael Paley¹, Lynn Hassman¹, Philip Ruzycki¹, Ekaterina Esaulova¹, Grace Paley¹, Jennifer Laurent¹, Luke Springer¹, Lacey Feigl¹, Maxim Artyomov¹ and Wayne Yokoyama², ¹Washington University, Saint Louis, ²Washington University, St Louis, MO
Background/Purpose: Anterior uveitis is a form of ocular inflammation associated with rheumatologic disease and can be categorized as granulomatous or non-granulomatous. Whether different ocular manifestations…
Abstract Number: 1229 • ACR Convergence 2020
Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
Eulalia Rodriguez-Martín¹, Israel Nieto-Gañán¹, Borja Hernández-Breijo², Cristina Sobrino³, Carlota García-Hoz¹, Javier Bachiller-Corral⁴, Ana Martínez-Feito⁵, Victoria Navarro-Compán⁶, Paloma Lapuente-Suanzes¹, Gema Bonilla⁷, Dora Pascual-Salcedo⁸, Garbiñe Roy¹, Teresa Jurado², Pilar Nozal², Mónica Vázquez⁴, Alejandro Balsa⁷, Luisa M Villar¹ and Chamaida Plasencia⁷, ¹Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ²Hospital Universitario La Paz-Idipaz, Madrid, Spain, ³Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁶Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁷Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFis) are widely used for the treatment of rheumatoid arthritis (RA), although the response rates to this therapy in patients with RA…
Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
Abstract Number: 1439 • ACR Convergence 2020
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis
Alvise Berti¹, Sophie Hillion², Marta Casal Moura¹, Amber Hummel¹, Eva Carmona¹, Tobias Peikert¹, Carol Langford³, Peter A. Merkel⁴, Paul Monach⁵, Philip Seo⁶, Robert Spiera⁷, Eugene St Clair⁸, Fernando C. Fervenza¹, Kristina Harris⁹, John H. Stone¹⁰, Jacques-Olivier Pers¹¹, Ulrich Specks¹ and Divi Cornec¹², ¹Mayo Clinic, Rochester, MN, ²Brest University, Brest, Bretagne, France, ³Cleveland Clinic, Moreland Hills, OH, ⁴Division of Rheumatology University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's, Boston, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁸Duke University, Durham, NC, ⁹Immune Tolerance Network, Bethesda, MD, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹University of Brest, Brest, France, ¹²Rheumatology Department, Brest University Hospital, Brest, France
Background/Purpose: In ANCA-associated vasculitis (AAV) B cells play a central pathogenic role and are instrumental for the production of ANCA, which are thought to mediate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].